DBV Technologies S.A. (DBVT)
NCM – Real Time Price. Currency in USD
16.01
-0.01 (-0.06%)
At close: Jun 26, 2026, 4:00 PM EDT
16.01
0.00 (0.00%)
After-hours: Jun 26, 2026, 4:10 PM EDT
Find any stock by ticker or company name

NCM – Real Time Price. Currency in USD
16.01
-0.01 (-0.06%)
At close: Jun 26, 2026, 4:00 PM EDT
16.01
0.00 (0.00%)
After-hours: Jun 26, 2026, 4:10 PM EDT
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
| Name | Position |
|---|---|
| Alan Kerr | Senior VP & Head of Global Regulatory Affairs |
| Dr. Kevin P. Malobisky M.S., Ph.D., R.A.C. | Chief Operations Officer |
| Dr. Pharis Mohideen M.D. | Chief Medical Officer |
| Mr. Daniel Tassé | CEO & Director |
| Mr. James Briggs | Chief Human Resources Officer |
| Mr. Jonathan Neely | VP & Head of Investor Relations |
| Mr. Kevin Trapp | Chief Commercial Officer |
| Mr. Pascal Wotling | Chief External Manufacturing & Supply Chain Officer |
| Ms. Michele F. Robertson | Chief Legal Officer |
| Ms. Virginie Simone Jeanine Verrechia Boucinha M.B.A. | Chief Financial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-06-05 | 8-K | d139789d8k.htm |
| 2026-06-04 | S-8 | d36002ds8.htm |
| 2026-06-03 | 8-K | d107628d8k.htm |
| 2026-05-11 | DEF 14A | d59776ddef14a.htm |
| 2026-05-11 | ARS | d14653dars.pdf |
| 2026-05-05 | 8-K | d150727d8k.htm |
| 2026-05-04 | S-8 | d151302ds8.htm |
| 2026-05-01 | PRE 14A | d59776dpre14a.htm |
| 2026-04-30 | 8-K | d132063d8k.htm |
| 2026-04-30 | 10-Q | dbvt-20260331.htm |